Drug profile · INN
tovorafenib
OJEMDA
tovorafenib (OJEMDA) is a raf serine/threonine protein kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tovorafenib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
tovorafenib (OJEMDA) is a raf serine/threonine protein kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
RAF serine/threonine protein kinase inhibitor
Primary target: RAF serine/threonine protein kinase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations
Ipsen secures conditional EU marketing authorization for Ojemda (tovorafenib) to treat pediatric low-grade glioma with BRAF alterations in patients 6 months and older.
Ipsen's Ojemda (Tovorafenib) Becomes First Targeted Therapy for Pediatric Brain Tumors in EU
Ipsen's Ojemda receives EU approval as first targeted therapy for pediatric low-grade glioma, addressing critical unmet need in rare brain tumors.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tovorafenib?
tovorafenib (OJEMDA) is a raf serine/threonine protein kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tovorafenib?
OJEMDA is a marketed brand name for tovorafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tovorafenib?
tovorafenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.